Cardio Diagnostics Holdings, Inc. (CDIO) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2024. Cardio Diagnostics Holdings, Inc. is a medical technology company developing AI-driven DNA biomarker testing for cardiovascular disease. The company operates as a smaller reporting company and an emerging growth company. Its primary products include the Epi+Gen CHD and PrecisionCHD clinical tests, alongside the HeartRisk intelligence platform.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $6,580 | $10,030 | $30,378 | $11,755 |
| Net Loss | $(1,412,566) | $(1,932,382) | $(6,864,145) | $(6,987,905) |
| Loss Per Share (Basic/Diluted) | $(0.06) | $(0.16) | $(0.30) | $(0.66) |
| Cash and Cash Equivalents | $1,982,590 (as of Sept 30, 2024) | |||
| Total Assets | $4,481,461 (as of Sept 30, 2024) | |||
| Total Liabilities | $795,276 (as of Sept 30, 2024) | |||
| Accumulated Deficit | $(21,232,525) (as of Sept 30, 2024) |
Liquidity & Debt: The company has no lines of credit. A finance agreement payable of $374,000 outstanding at year-end 2023 was fully paid off during the period. The company raised approximately $5.18 million in gross proceeds from the sale of common stock and warrants during the nine months ended September 30, 2024.
Material Changes vs. Prior Period
- Revenue Growth: Year-to-date revenue increased by approximately 158% compared to the prior year ($30,378 vs. $11,755), driven by expanded commercialization efforts. However, Q3 2024 revenue declined slightly compared to Q3 2023.
- Net Loss Reduction: Net loss decreased for both the quarter and the year-to-date period. The Q3 2024 loss was $519,816 lower than Q3 2023, and the YTD loss was $123,760 lower. This improvement is primarily attributed to a significant reduction in interest expenses related to convertible debentures issued in 2023.
- Operating Expenses: General and Administrative (G&A) expenses increased by $1.25 million YTD, largely due to a $1.35 million increase in stock-based compensation from new option grants in Q1 2024. Research and Development (R&D) expenses decreased significantly ($114,323 YTD) due to fewer laboratory runs for new product offerings.
- Capital Structure: The company issued 9.17 million shares via an At-the-Market (ATM) offering and 561,793 shares via a private placement during the nine-month period, increasing outstanding shares from 20.5 million to 30.3 million.
Outlook, Risks, and Contingencies
- Going Concern: The filing includes a "Going Concern" warning. With an accumulated deficit of over $21 million and nominal revenue, the company's ability to continue operations depends on securing additional equity financing. Management believes current funds and anticipated financing will suffice for the next 12 months.
- Nasdaq Compliance: The company received notice from Nasdaq on June 3, 2024, regarding non-compliance with the minimum $1.00 bid price requirement. It has an initial 180-day cure period ending December 2, 2024, to regain compliance, with a potential extension to May 29, 2025. Failure to comply could result in delisting.
- Regulatory Risks (FDA): The FDA's new final rule regarding Laboratory Developed Tests (LDTs) will phase in regulatory requirements starting May 6, 2025. This may require costly premarket authorizations for the company's tests. Litigation challenging this rule is ongoing.
- Legal Contingencies: The company is evaluating claims from The Benchmark Company, LLC regarding a right of first refusal on financing transactions. Additionally, a securities law firm has sent a demand letter regarding the S-4 registration statement, though no lawsuit has been filed.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2024.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.98 million cash balance against the projected burn rate and the timeline for the next equity raise.
- Nasdaq Status: Monitor the stock price relative to the $1.00 threshold and the company's progress toward regaining compliance by December 2, 2024.
- FDA Compliance Costs: Assess the potential financial impact of the new FDA LDT regulations on the company's ability to market its core products.
- Dilution Risk: Review the terms of the ATM offering and potential future equity issuances, noting the significant increase in share count (from ~20.5M to ~30.3M) in the last nine months.
- Revenue Sustainability: Evaluate the durability of the YTD revenue growth given the decline in Q3 revenue and the long sales cycles mentioned in the MD&A.